Melanotan 1 (Afamelanotide/Scenesse) for Photoprotection — Skin & Hair
FDA-approved MC1R agonist for erythropoietic protoporphyria (EPP). Selective melanin stimulation. Implant formulation. Safer than Melanotan II.
Overview
Melanotan 1 (Afamelanotide, brand name Scenesse) is a synthetic 13-amino acid analog of alpha-melanocyte-stimulating hormone (alpha-MSH). FDA-APPROVED (October 2019) to increase pain-free light exposure in adults with erythropoietic protoporphyria (EPP). Also EMA-approved since 2014. KEY DIFFERENTIATOR FROM MELANOTAN II: Melanotan 1 is a SELECTIVE MC1R agonist — it does NOT activate MC3R or MC4R receptors, meaning it does NOT cause the sexual arousal, nausea, or appetite suppression associated with Melanotan II. This makes it significantly safer. MECHANISM: Stimulates eumelanin production in the skin, providing photoprotection through UV absorption, antioxidant activity, DNA repair enhancement, and anti-inflammatory effects. ADMINISTRATION: Unique 16mg bioresorbable subcutaneous implant providing controlled release over ~2 months. Only 3-4 implants needed per year. FDA TRIAL DATA: Patients could spend 64 hours in direct sunlight without pain vs 41 hours for placebo. COST: ~$48,400 per implant (~$145,000-193,000/year) — orphan drug pricing. IMPORTANT: Must be administered by trained healthcare professionals using specialized implantation cannula. 91% of real-world patients continue treatment.
Indications
- Erythropoietic protoporphyria (EPP) - FDA-APPROVED (increased pain-free light exposure)
- Photoprotection via eumelanin stimulation
- Vitiligo (Phase 2/3 clinical trials ongoing)
- Xeroderma pigmentosum (clinical trials recruiting)
- Polymorphous light eruption (early studies, promising)
- Solar urticaria (early studies)
- Actinic keratosis prevention in organ transplant recipients (early data)
- Hailey-Hailey disease (early data)
Mechanism of Action
Erythropoietic protoporphyria causes accumulation of protoporphyrin IX. Light activates PPIX causing severe skin pain, burning, redness, and thickening. Patients typically avoid sunlight, severely limiting daily activities
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Afamelanotide (Scenesse) | 16 mg implant | Every 2 months (3-4 implants per year) | FDA-approved. Bioresorbable rod (1.7cm x 1.5mm). Inserted above anterior suprailiac crest (hip area). |
Evidence Grade
GRADE A
Safety & Contraindications
- Afamelanotide (Scenesse) is FDA-approved ONLY for erythropoietic protoporphyria (EPP), a rare condition causing severe sun sensitivity — NOT approved for cosmetic skin tanning
- Scenesse is a subcutaneous implant manufactured by Clinuvel Pharmaceuticals, administered by healthcare professionals only
- Melanotan 1 as a standalone peptide (non-Scenesse) is NOT FDA-approved for any indication
- GENERALIZED SKIN HYPERPIGMENTATION IS EXPECTED (darkening of skin, nevi, freckles)
- Full-body skin exam required TWICE YEARLY (monitor for new/changing pigmented lesions)
- Hypersensitivity reactions including anaphylaxis reported post-marketing
- Continue sun protection measures (sunscreen, clothing) DESPITE treatment
- Avoid driving/heavy machinery for 72 hours post-implantation (fatigue, dizziness)
- Common side effects: implant site reactions (21%), nausea (19%), throat pain (7%), fatigue (6%), dizziness (4%)
- NOT hepatotoxic - no clinically meaningful enzyme elevations
- No adequate human pregnancy data (animal studies showed no harm at 12x human dose)
- Must be administered by trained healthcare professional with specialized cannula
- Patient monitored for 30 minutes post-implantation (allergic reaction risk)